Notable Price Action: Can FibroGen Inc’s Tomorrow Be Different? The Stock Increases Again

Notable Price Action: Can FibroGen Inc's Tomorrow Be Different? The Stock Increases Again

The stock of FibroGen Inc (NASDAQ:FGEN) is a huge mover today! About 304,212 shares traded hands. FibroGen Inc (NASDAQ:FGEN) has declined 25.71% since April 4, 2016 and is downtrending. It has underperformed by 26.80% the S&P500.
The move comes after 6 months positive chart setup for the $995.87 million company. It was reported on Nov, 4 by Barchart.com. We have $20.19 PT which if reached, will make NASDAQ:FGEN worth $248.97 million more.

Analysts await FibroGen Inc (NASDAQ:FGEN) to report earnings on November, 10. They expect $-0.60 earnings per share, up 18.92% or $0.14 from last year’s $-0.74 per share. After $0.35 actual earnings per share reported by FibroGen Inc for the previous quarter, Wall Street now forecasts -271.43% negative EPS growth.

FibroGen Inc (NASDAQ:FGEN) Ratings Coverage

Out of 3 analysts covering FibroGen Inc (NASDAQ:FGEN), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. FibroGen Inc has been the topic of 6 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Credit Suisse initiated FibroGen Inc (NASDAQ:FGEN) on Thursday, January 21 with “Neutral” rating. On Thursday, February 11 the stock rating was upgraded by Credit Suisse to “Outperform”. Lake Street initiated it with “Hold” rating and $25 target price in Wednesday, September 23 report. The company was initiated on Friday, December 4 by Citigroup. The stock has “Buy” rating given by Citigroup on Wednesday, July 29.

According to Zacks Investment Research, “FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.”

More news for FibroGen Inc (NASDAQ:FGEN) were recently published by: Marketwatch.com, which released: “FibroGen Inc. NASDAQ: FGEN” on November 20, 2012. Quotes.Wsj.com‘s article titled: “FibroGen Inc. FGEN (US: Nasdaq)” and published on November 08, 2014 is yet another important article.

FGEN Company Profile

FibroGen, Inc., incorporated on September 29, 1993, is a research biopharmaceutical company. The Firm is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The Firm focuses in the areas of fibrosis and hypoxia-inducible factor (HIF) biology and generates multiple programs targeting various therapeutic areas. The Company’s lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment